Contrasting effects of allosteric and orthosteric agonists on M1 muscarinic acetylcholine receptor internalization and down-regulation

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 1086-1095

  Thomas, Rachel L ^a   Langmead, Christopher J ^b   Wood, Martyn D ^b   Challiss, R A John ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BUTYL 1 PIPERIDINYL) PROPYL] 3,4 DIHYDRO 2(1H) QUINOLINONE; 4 N BUTYL 1 [4 (2 METHYLPHENYL) 4 OXO 1 BUTYL] PIPERIDINE; AC 42; ARECOLINE; ATROPINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; OXOTREMORINE M; PHOSPHATIDYLINOSITIDE; PILOCARPINE; UNCLASSIFIED DRUG; 1 (3 (4 BUTYL 1 PIPERIDINYL)PROPYL) 3,4 DIHYDRO 2(1H) QUINOLINONE; 1-(3-(4-BUTYL-1-PIPERIDINYL)PROPYL)-3,4-DIHYDRO-2(1H)-QUINOLINONE; 4 N BUTYL 1 (4 (2 METHYLPHENYL) 4 OXO 1 BUTYL) PIPERIDINE HYDROGEN CHLORIDE; 4-N-BUTYL-1-(4-(2-METHYLPHENYL)-4-OXO-1-BUTYL)-PIPERIDINE HYDROGEN CHLORIDE; LIGAND; MUSCARINIC AGENT; PIPERIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LEVEL; CHO CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG STABILITY; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BINDING SITE; BIOSYNTHESIS; CRICETULUS; DRUG POTENTIATION; HAMSTER; PROTEIN BINDING; RADIOASSAY; WESTERN BLOTTING;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; DOWN-REGULATION; LIGANDS; MUSCARINIC AGONISTS; PIPERIDINES; PROTEIN BINDING; QUINOLONES; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; SIGNAL TRANSDUCTION;

EID: 73349107462     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160242     Document Type: Article

References (40)

1. Bartolomeo AC, Morris H, Buccafusco JJ, Kille N, Rosenzweig-Lipson S, Husbands MG, Sabb AL, Abou-Gharbia M, Moyer JA, and Boast CA (2000) The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. J Pharmacol Exp Ther 292:584-596.
2. Birdsall NJ and Lazareno S (2005) Allosterism at muscarinic receptors: ligands and mechanisms. Mini-Rev Med Chem 5:523-543.
3. Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp N, Shannon HE, et al. (1998) Xanomeline compared with other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 795:179-190.
4. Caulfield MP and Birdsall NJ (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279-290.
5. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
6. 1 muscarinic acetylcholine receptors without inducing adaptive changes. Society for Neuroscience, Washington DC. Abstract nr 149.5.
7. 3 muscarinic acetylcholine receptor reveals differences in the properties of antagonists: evidence for differential inverse agonism. J Pharmacol Exp Ther 317:1134-1142.
8. Eglen RM, Choppin A, Dillon MP, and Hegde S (1999) Muscarinic receptor ligands and their therapeutic potential. Curr Opin Chem Biol 3:426-432.
9. Felder CC, Bymaster FP, Ward J, and DeLapp N (2000) Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 43:4333-4353.
10. Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24.
11. Gregory KJ, Sexton PM, and Christopoulos A (2007) Allosteric modulation of muscarinic acetylcholine receptors Curr Neuropharmacol 5:157-167.
12. Haga K, Kameyama K, Haga T, Kikkawa U, Shiozaki K, and Uchiyama H (1996) Phosphorylation of human m1 muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 and protein kinase C. J Biol Chem 271:2776-2782.
13. Hulme EC, Lu ZL, Saldanha JW, and Bee MS (2003) Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 31:29-34.
14. 1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28:10422-10433.
15. Lameh J, Philip M, Sharma YK, Moro O, Ramachandran J, and SadéeW(1992) Hm1 muscarinic cholinergic receptor internalization requires a domain in the third cytoplasmic loop. J Biol Chem 267:13406- 13412.
16. Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, Forbes IT, Fry VA, Hagan JJ, Herdon HJ, et al. (2008a) Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 154:1104-1115.
17. Langmead CJ and Christopoulos A (2006) Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 27:475-481.
18. 1 receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 69:236-246.
19. Langmead CJ, Watson J, and Reavill C (2008b) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117:232-243.
20. Lebon G, Langmead CJ, Tehan BG, and Hulme EC (2009) Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol Pharmacol 75:331-341.
21. 1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A, doi: 10.1073/pnas.0900903106.
22. Maloteaux JM, Gossuin A, Pauwels PJ, and Laduron PM (1983) Short-term disappearance of muscarinic cell surface receptors in carbachol-induced desensitization. FEBS Lett 156:103-107.
23. 1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 75:577-588.
24. 2 muscarinic acetylcholine receptors. Mol Pharmacol 72:463-476.
25. 2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators. J Pharmacol Exp Ther 312:382-390.
26. Milligan G and Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18:468-474.
27. s proteins. Br J Pharmacol 144: 566-575.
28. 2 muscarinic acetylcholine receptors. J Mol Signal 3:20.
29. Pelkey KA, Yuan X, Lavezzaqri G, Roche KW, and McBain CJ (2007) mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082. Neuropharmacology 52:108-117.
30. Santini F, Penn RB, Gagnon AW, Benovic JL, and Keen JH (2000) Selective recruitment of arrestin-3 to clathrin coated pits upon stimulation of G protein-coupled receptors. J Cell Sci 113:2463-2470.
31. 4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 4:42-50.
32. 2 receptors. Proc Natl Acad Sci U S A 93:6802-6807.
33. 1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol Pharmacol 70:1974-1983.
34. 1 muscarinic receptor. Mol Pharmacol 61:1297-1302.
35. 1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther 327:365-374.
36. van Koppen CJ and Kaiser B (2003) Regulation of muscarinic acetylcholine receptor signaling. Pharmacol Ther 98:197-220.
37. Vögler O, Nolte B, Voss M, Schmidt M, Jakobs KH, and van Koppen CJ (1999) Regulation of muscarinic acetylcholine receptor sequestration and function by β-arrestin. J Biol Chem 274:12333-12338.
38. Waugh MG, Challiss RA, Berstein G, Nahorski SR, and Tobin AB (1999) Agonist-induced desensitization and phosphorylation of m1-muscarinic receptors. Biochem J 338:175-183.
39. Wess J (1996) Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 10:69-99.
40. 1 muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 in hippocampal neurons. J Biol Chem 280:18950-18958.